Selected Start-Ups (01/01)
Executive SummaryIn Vivo summarizes the technologies of several recently founded companies: Advanced BioChem Inc. provides contract protein biochemistry, immunoassay and proteomics services to companies developing pharmaceuticals and medical diagnostics tests. Arradial Inc. aims to accelerate the discovery and validation of therapeutic compounds with a personal desktop laboratory microarray screening system created jointly by Boston University and Alexion Pharmaceuticals Inc. Spun out of Evotec BioSystems AG, Direvo Biotech AG will use its directed evolution platform to optimize biomolecules for industrial applications, as well as to develop proteins for novel therapeutics. Evacyte Microarray Diagnostics Corp.'s new cancer detection device, the Optical Stretcher, uses laser beams to stretch individual cells, enabling doctors to extract very small samples to determine if cancer cells are present. Palumed SA is developing small molecule drugs for the treatment of malaria and other infectious diseases. Using technology developed by its founders at the University of Texas' MD Anderson Cancer Center and in collaboration with Tripos Inc., Signase Inc. will develop small-molecule inhibitors of protein tyrosine kinases to enhance the effectiveness of chemotherapy directed at various types of solid tumors.
You may also be interested in...
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.